Evidence map›Paper›PMID 36505839›Full record

ArticleFrontiers in oncology2022

A multicenter, open-label study for efficacy and safety evaluation of anagrelide in patients with treatment-naïve, high-risk essential thrombocythemia as a primary treatment.

Ja Min Byun, Ho Young Kim, Seung-Hyun Nam, Ho-Jin Shin, Seulki Song, Jinny Park, Sang Hoon Han, Yong Park, Young Jin Yuh, Yeung-Chul Mun and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 12 institutions in 1 country.

Ja Min ByunDepartment of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.
Ho Young KimDepartment of Internal Medicine, Hallym University Medical Center, Anyang, South Korea.
Seung-Hyun NamDepartment of Internal Medicine, Kyung Hee University at Gangdong, Seoul, South Korea.
Ho-Jin ShinDivision of Haematology-Oncology, Department of Internal Medicine, School of Medicine, Medical Research Institute, Pusan National University Hospital, Busan, South Korea.
Seulki SongCancer Research Institute, Seoul National University Hospital, Seoul, South Korea.
Jinny ParkDivision of Hematology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, South Korea.
Sang Hoon HanDepartment of Internal Medicine, Jeju National University Hospital, Jeju National University School of Medicine, Jeju, South Korea.
Yong ParkDivision of Hemato-Oncology, Department of internal medicine, Korea University School of Medicine, Seoul, South Korea.
Young Jin YuhDepartment of Internal Medicine, Inje University College of Medicine, Sanggye Paik Hospital, Seoul, South Korea.
Yeung-Chul MunDepartment of Internal Medicine, Ewha Womans University Mokdong Hospital, Ewha Womans University College of Medicine, Seoul, South Korea.
Young Rok DoDepartment of Internal Medicine, Keimyung University Dongsan Hospital, Keimyung University School of Medicine, Daegu, South Korea.
Sang Kyun SohnDepartment of Internal Medicine, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu, South Korea.
Sung Hwa BaeDepartment of Internal Medicine, Daegu Catholic University School of Medicine, Daegu, South Korea.
Dong-Yeop ShinDepartment of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.
Sung-Soo YoonDepartment of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.
Seoul National University Hospital · KRDaegu Catholic University · KREwha Womans University · KRGachon University Gil Medical Center · KRHallym University Medical Center · KRInje University Sanggye Paik Hospital · KRJeju National University Hospital · KRKeimyung University · KRKorea University · KRKyung Hee University Hospital at Gangdong · KRKyungpook National University Hospital · KRPusan National University Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As the discussion of first-line anagrelide treatment is ongoing, we aimed to prospectively examine the efficacy and safety of anagrelide in cytoreduction therapy-naïve high risk essential thrombocythemia (ET) patients in Korea. Seventy patients from 12 centers were treated with anagrelide monotherapy for up to 8 weeks, followed up until 24 months. At week 8, 50.0% of the patients were able to achieve platelet < 600 x 10

Indexed as

Anagrelideessential thrombocythemiahigh riskmyeloproliferative neoplasmsphase IV clinical trial

Identifiers

PMID36505839
PMCPMC9727180
OpenAlexW4309707071

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.